Kaplan‒Meier survival analyses of patients with GBM based on RhoA, RhoB, RhoC, DIAPH1, PFN1, and MYPT1 gene expression (Fig. 1E) suggested that high expression of RHOA, RHOC, DIAPH1 and PFN1, low expression of RHOB and MYPT1, or both may be markers of poor prognosis in GBM patients. The gene discussed is PPP1R12A; the disease is glioblastoma.